{"name":"Janssen Biotech, Inc.","slug":"janssen-biotech-inc","ticker":"","exchange":"","domain":"janssen.com","description":"Johnson & Johnson Innovative Medicine is a Belgian pharmaceutical company headquartered in Beerse, Belgium, and wholly owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen.","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Anti TNF therapy including infliximab","genericName":"Anti TNF therapy including infliximab","slug":"anti-tnf-therapy-including-infliximab","indication":"Rheumatoid Arthritis","status":"phase_2"}]}],"pipeline":[{"name":"Anti TNF therapy including infliximab","genericName":"Anti TNF therapy including infliximab","slug":"anti-tnf-therapy-including-infliximab","phase":"phase_2","mechanism":"Blocks tumor necrosis factor-alpha (TNF-alpha) by binding to it and preventing it from interacting with cell surface TNF receptors.","indications":["Rheumatoid Arthritis","Psoriatic Arthritis","Ulcerative Colitis","Crohn's Disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-03","type":"regulatory","source":"CNBC TV18","summary":"NATCO Pharma gets USFDA nod for generic cancer drug Erdafitinib; shares jump 3% - CNBC TV18","headline":"NATCO Pharma gets USFDA nod for generic cancer drug Erdafitinib; shares jump 3% - CNBC TV18","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPdG1Dcjl0Rk9iejNVMC1UQ2VoM1RuTzh1cm82b2Q3TW1ST2JVMXRUM1JpYjNGYWp3bm5jR0VsRmZSZlJYZU5xME5RclVuU0FKcWlrVlhTV3YwOFhjdnJ1RXZoQ1dmanhocGNSaGdFUThhSnZpTG9OdEVsNlNJX2U0elZ3RURLSHM3TUE?oc=5","date":"2026-01-22","type":"pipeline","source":"Manhattan Institute","summary":"Amicus Brief: Janssen Pharmaceuticals v. Kennedy - Manhattan Institute","headline":"Amicus Brief: Janssen Pharmaceuticals v. Kennedy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNc2I3U1hVdlVGZWZlcGw0ODUxOElpaDVjYjJIbTRfQVFCNTZEcm5fQVY3dEIxZndrWXZZREhTUE1tYTcxRGFIbmh0dFVBaWNzVEwzOVFUTzRDRE1pam1LOE1nUnUtZmdCbkI0UmN2bV8zUzUyWlpheFd6WVBFTmpTYXBnSC11TWVicVZjaXd6UlZtc3FyeXNhUENvQnd5ZURITTFJbnRBSDR3bTFGSzNCR09lVUpSRkNmbFFYQ3A3cw?oc=5","date":"2024-10-01","type":"regulatory","source":"WRAL","summary":"Officials approve incentives worth up to $79.9M for J&J unit eyeing $2B plant in Wilson - WRAL","headline":"Officials approve incentives worth up to $79.9M for J&J unit eyeing $2B plant in Wilson","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA4RlVlSTBkbl9KTUtHNGZ6OUZPbkpudVVhM2NZdUlESGxRUmJIWXZZUEd4UWNOZy1hZnZJVDlacDFyWU1jN215Um9mT01LNlo0TDZ0WW9yWXJQRDJWUnoxUVcyWE42dlZwVGpnSzFn?oc=5","date":"2023-12-26","type":"deal","source":"KED Global","summary":"LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal - KED Global","headline":"LegoChem Bio, Janssen sign $1.7 bn ADC licensing deal","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2022-04-18","type":"pipeline","source":"PBS","summary":"Johnson & Johnson subsidiary settles West Virginia opioid lawsuit for $99 million - PBS","headline":"Johnson & Johnson subsidiary settles West Virginia opioid lawsuit for $99 million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNZ0NaQVZSOFhrM2pCSURRTkFTUWJrbjhPdVptS0UyQlM0N29yZGlhR3I5UlFma0JnSGdOV1pZNmYweXNiMFZ2OWkxRWt2M1ZyN3NiOHNOVjY2V0MyTUoxVWotYzVCWDNTRExxT2xpWlBHS29RSUM0ZG12RVBWZjdYMjlvSk9KQ3hZNkNzdEU5WS1lVS1uV0xNUVVIN182clZxWE91MEZkeXNpdE0z?oc=5","date":"2022-02-17","type":"deal","source":"Fierce Biotech","summary":"Remix Therapeutics signs Janssen licensing deal that could top $1B - Fierce Biotech","headline":"Remix Therapeutics signs Janssen licensing deal that could top $1B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOamxJeF9YWHZvOHpXeEZSd0NKUmJHY1hvSE1STlRZSkhEZ1BzLUl6NlNrd1ZfOFFjaXdpOFdCcndFSFhOOTRScy1MSjhNLXVWUWttVDVDWFRxd2xUSVVIZzg3WnpKVVZxdG90S3N3LWVOOGh0cVR6UHplT3BueWppU04yVnZMREEzVlRPN0ROSmlfYlIzT1UtMkxrcFB4QTFxVlZxSWloMGo3TXVQZ09jX2FJODBvRk1aRjNvSnlOajg0UWlZMGw1ajNR?oc=5","date":"2021-05-31","type":"pipeline","source":"The Quantum Insider","summary":"Qu&Co, Janssen Pharmaceuticals to Develop and Test Quantum Computational Methods Pharma R&D - The Quantum Insider","headline":"Qu&Co, Janssen Pharmaceuticals to Develop and Test Quantum Computational Methods Pharma R&D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPZTMyVzNhYllpVHc4cHZaYU1PSU5jeWlEVzB6REFxY2h6VlJvRDlRbGdmQTZDOFZIVVJydmp0QnpNSE1DRUpaSnc2X19mejFmZ2YtYzNoblZLYlNvVXdXdzR2REtVS1k0WGVhaXRoRmpMUnNxeV9lMEVTVjBDNjRWSDhPM3Q4QmVRaFdRQVJDOWFlajVYTnMw?oc=5","date":"2020-12-08","type":"pipeline","source":"Los Angeles Business Journal","summary":"Xencor Inks Licensing Agreement with Janssen Biotech - Los Angeles Business Journal","headline":"Xencor Inks Licensing Agreement with Janssen Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPblRDanZsZ1FzanF1RmM3djdaV3phdzFLOFQ0anRjRkliUmVfWFg1SXdUMl9CMzJTWEZLazNISDBqLUxXQ2R0SXNCZktfNWZkVnA3RDQ1WGViOTlJN0txM3lKV1B0bEkzdEM0d2NuVzFOYTRINlpuZjVQTG5Cak5KQnM3RWllbVNWVVJ5VF84R3hZV0EwZ3dHUVlQNHBXcTFvNHFCeXJNekFDSER4cDZUcG5PbVZENG5LQ3pacnBRWjRSRFFGUGRKTnJwdVQzRmhkczlMaGFILUxYeFhNVFpnZQ?oc=5","date":"2019-12-30","type":"pipeline","source":"PR Newswire","summary":"Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc. - PR Newswire","headline":"Janssen Announces Completion of Acquisition of Investigational Bermekimab from XBiotech Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOSXJRZ04weFNrMHh0a2JxdndHMnk0SHJ4OWxTRnRKckF4RTF3eDJZRDlRWGZjYlNtSTVISzhPQnEzNzFoa21OS2JnZXc4UWtPTC1QOVVSeDdCajFCTUJoVUEzSFJkczk5X1VOVlY3WC12RlRNejdUMVVxT211WEdMU0s5UlEyTDM3TWpuVlhBOExSZk9zeWRFTjU3ZWVVbDNyOGFaVzNESWhQOVNoZWF2eV93M0M4RERYci1kUV8xRG12WDZrdW9pZTh3?oc=5","date":"2018-10-04","type":"deal","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Enters $3.7 Billion License and Collaboration Agreements with Janssen - Arrowhead Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNbHlST0pEWGRsZ0xSQ0pHU2dJVVVYT3NlZEJibTFKc0s5SnYxTVNKMXFxNEt3a1hFaEtMeEZreTluRFJHQ1VrTm1leThJMk1HQlV1NFB2VTNyVG40WENGanBEQWVvU3JCTUtBZzh1T1JaY3pqU3hFMm5Vam1SX0VFRk84djBhamEzTXI3QzZtbVNadVRKNEFVdXJfb25qZV81cUHSAacBQVVfeXFMTW9vc242TGJ2dnBza1BLM0RtSzhORWtrNU83aEZ5SVZXR3hzcHVVOWVsbjB2anR3dWpObVl2aXZ0SmZUd0xlYlNCU3JVeWpCVjRndk9LRkZyRVgtS3p6MXZLN2pBRnBGVHM1OE9YUUNPZmxCNml4VW50N1dlSWZEamxKVjJseHByeHZKU3JpVHZUUk8yWnFYNUlBaU9OS0xscXV5eDh5YzA?oc=5","date":"2017-12-23","type":"deal","source":"BioInformant","summary":"J&J to Compete in CAR-T: Subsidiary Janssen Biotech Signs $350M Deal with Legend Biotech - BioInformant","headline":"J&J to Compete in CAR-T: Subsidiary Janssen Biotech Signs $350M Deal with Legend Biotech","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPUTBiNnBxcTJOV1dNZ2kycXNBLTIwb0R4cDI2RzFHREEtU1RsSERDTUdqd0J0N09jNnpjWjhtdUdtUjh2VGJwWWczWDdlaWFXY1hfUldFNTFBbjB0R1hqNVJ6b2xUX095T2JyYXBqME9iaW9RRERNQ1ZBcVU2YTJZZXgycndqc1Z4cWx2cTlYSWI2Z0hLdzZj?oc=5","date":"2017-02-27","type":"pipeline","source":"Johnson & Johnson","summary":"Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report - Johnson & Johnson","headline":"Janssen Pharmaceuticals releases a 2016 U.S. Transparency Report - Johnson & Johnson","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}